AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22101095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (ITG)
Number of subjects: 60
Study 22101095 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 60
Study 19579617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuver (Group 1)
Number of subjects: 94
Study 19579617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemihepatic inflow control (Group 2)
Number of subjects: 94
Study 19579617 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete hemihepatic vascular occlusion with hanging maneuver (Group 3)
Number of subjects: 94
Study 17456839 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin (12 units)
Number of subjects: 45
Study 17456839 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin lispro (12 units)
Number of subjects: 45
Study 17456839 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin
Number of subjects: 45
Study 15645892 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Supreme
Number of subjects: 29
Study 15645892 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips
Number of subjects: 29
Study 11714206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension clinic
Number of subjects: 330
Study 11714206 — intervention group
Group type: COMPARATOR
Intervention: Physician-managed clinic
Number of subjects: 330
Study 9160847 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (average daily intake)
Number of subjects: 0
Study 9160847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9160847 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 7949515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 0
Study 7949515 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccine
Number of subjects: 0
Study 7949515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral or intranasal formulations of pertussis vaccine
Number of subjects: 0
Study 3586805 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinflation using a modified Valsalva technique with an anesthesia mask and flowmeter
Number of subjects: 35
Study 3586805 — intervention group
Group type: COMPARATOR
Intervention: Traditional method using preinflation and postinflation tympanometry
Number of subjects: 35
Study 31088557 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing in a fall prevention exercise program
Number of subjects: 58
Study 31088557 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meetings and follow-ups during treatment period
Number of subjects: 58
Study 28422846 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (80-2/3* age) combined with propofol (20-30 mg) for 1 to 2 minutes during ERCP and EST surgery
Number of subjects: 68
Study 28422846 — intervention group
Group type: COMPARATOR
Intervention: Sedative drugs not given
Number of subjects: 68
Study 26040075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contextual interference
Number of subjects: 57
Study 26040075 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate contextual interference
Number of subjects: 57
Study 26040075 — intervention group
Group type: COMPARATOR
Intervention: High contextual interference
Number of subjects: 57
Study 25146074 — intervention group
Group type: EXPERIMENTAL
Intervention: MYCaW questionnaire
Number of subjects: 31
Study 25146074 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 31
Study 25146074 — intervention group
Group type: EXPERIMENTAL
Intervention: Priority list of outcome areas
Number of subjects: 31
Study 22963737 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy condition
Number of subjects: 352
Study 22963737 — intervention group
Group type: COMPARATOR
Intervention: Diet condition
Number of subjects: 352
Study 22963737 — intervention group
Group type: COMPARATOR
Intervention: Hedonic condition
Number of subjects: 352
Study 22963737 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight vs. Overweight/Obese
Number of subjects: 352
Study 22963737 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint status (unrestrained vs. restrained eaters)
Number of subjects: 352
Study 19304716 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium dosage of 450 mg I/kg of estimated lean body weight (LBW)
Number of subjects: 97
Study 19304716 — intervention group
Group type: COMPARATOR
Intervention: Contrast medium dosage of 360 mg I/kg of total body weight (TBW)
Number of subjects: 97
Study 19304716 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated LBW group
Number of subjects: 97
Study 19304716 — intervention group
Group type: COMPARATOR
Intervention: TBW group
Number of subjects: 97
Study 17510758 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine 50 mg
Number of subjects: 48
Study 17510758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15388432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g intravenously once daily for 7 days
Number of subjects: 10
Study 15388432 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g intravenously once daily for 7 days
Number of subjects: 10
Study 15388432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antibiotics
Number of subjects: 10
Study 11820227 — intervention group
Group type: EXPERIMENTAL
Intervention: New nursing intervention to manage breathlessness
Number of subjects: 0
Study 9806670 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 80
Study 9806670 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5
Number of subjects: 80
Study 9806670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HES solutions
Number of subjects: 80
Study 7703045 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (10 mg/kg i.v. every 6 hours, day‐5 to +1)
Number of subjects: 155
Study 7703045 — intervention group
Group type: COMPARATOR
Intervention: Control group (without vancomycin)
Number of subjects: 155
Study 2781421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 33
Study 2781421 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 33
Study 1032878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 100
Study 1032878 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 100
Study 31076949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Adaptation (DA)
Number of subjects: 0
Study 31076949 — intervention group
Group type: COMPARATOR
Intervention: Light Adaptation (Control)
Number of subjects: 0
Study 28488142 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrating nail solution (HNS) applied once a day until grade 2 onycholysis, then twice a day thereafter.
Number of subjects: 103
Study 28488142 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 103
Study 25238728 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVR) using different endograft systems (Zenith, Excluder, AneuRx)
Number of subjects: 881
Study 25238728 — intervention group
Group type: COMPARATOR
Intervention: Open repair (control)
Number of subjects: 881
Study 25238728 — intervention group
Group type: COMPARATOR
Intervention: Endovascular repair (EVR) compared to open repair
Number of subjects: 881
Study 24060673 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-targeted, community-based lifestyle intervention consisting of 6 weeks of group classes followed by 12 weeks of individual telephone support.
Number of subjects: 0
Study 24060673 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving screening results and monthly mailings on CVD prevention.
Number of subjects: 0
Study 24060673 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-targeted, community-based lifestyle intervention.
Number of subjects: 0
Study 24060673 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 0
Study 21729342 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutically induced change interventions
Number of subjects: 281
Study 19701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak LC Bond with self-etching technique on fluorotic enamel
Number of subjects: 72
Study 19701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak LC Bond with self-etching technique on nonfluorotic enamel
Number of subjects: 72
Study 19701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak LC Bond with etch-and-rinse technique on fluorotic enamel
Number of subjects: 72
Study 19701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak LC Bond with etch-and-rinse technique on nonfluorotic enamel
Number of subjects: 72
Study 19701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno V one-bottle self-etching on fluorotic enamel
Number of subjects: 72
Study 19701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno V one-bottle self-etching on nonfluorotic enamel
Number of subjects: 72
Study 16822276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene (0.25 mg) with ketoconazole (400 mg daily x 20 days)
Number of subjects: 65
Study 16822276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene (0.25 mg) with fluconazole (400 mg daily x 20 days)
Number of subjects: 65
Study 16822276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene (0.25 mg) with paroxetine (30 mg qd x 21 days)
Number of subjects: 65
Study 16822276 — intervention group
Group type: COMPARATOR
Intervention: Lasofoxifene (0.25 mg) alone
Number of subjects: 65
Study 15193896 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough skin self-examination (TSSE)
Number of subjects: 2126
Study 15193896 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a partner to assist in TSSE
Number of subjects: 2126
Study 15193896 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of a wall mirror
Number of subjects: 2126
Study 15193896 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 2126
Study 11434709 — intervention group
Group type: EXPERIMENTAL
Intervention: Free TFPI (f‐TFPI)
Number of subjects: 626
Study 11434709 — intervention group
Group type: EXPERIMENTAL
Intervention: Total TFPI (t‐TFPI)
Number of subjects: 626
Study 9595996 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic thoracic outlet syndrome
Number of subjects: 24
Study 9595996 — intervention group
Group type: COMPARATOR
Intervention: Sternotomy-related brachial plexopathy
Number of subjects: 24
Study 8044386 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg
Number of subjects: 46
Study 8044386 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 300 U/kg
Number of subjects: 46
Study 8044386 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 600 U/kg
Number of subjects: 46
Study 8044386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2223168 — intervention group
Group type: EXPERIMENTAL
Intervention: Group instruction
Number of subjects: 783
Study 2223168 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual instruction
Number of subjects: 783
Study 2223168 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual instruction with a reminder system
Number of subjects: 783
Study 2223168 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 783
Study 798709 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 6
Study 798709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6
Study 798709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6
Study 798709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol-Isosorbide dinitrate (combination)
Number of subjects: 6
Study 798709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol-Nifedipine (combination)
Number of subjects: 6
Study 798709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30782014 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-guided pain coping skills training intervention
Number of subjects: 214
Study 30782014 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (Control)
Number of subjects: 214
Study 28777983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 5000 IU po qday for 12 weeks
Number of subjects: 33
Study 28777983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25767183 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroCoil
Number of subjects: 288
Study 25767183 — intervention group
Group type: COMPARATOR
Intervention: bare-platinum coils
Number of subjects: 288
Study 23237137 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 1339
Study 23237137 — intervention group
Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (E-ZES)
Number of subjects: 1339
Study 16823652 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic feedback training
Number of subjects: 38
Study 16823652 — intervention group
Group type: COMPARATOR
Intervention: Nonhaptic training
Number of subjects: 38
Study 12598993 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 20 mg of butylscopolamine 10 min before MR examination
Number of subjects: 50
Study 12598993 — intervention group
Group type: COMPARATOR
Intervention: Control group received only an oral solution
Number of subjects: 50
Study 12598993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 10578460 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal rTMS
Number of subjects: 35
Study 10578460 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 35
Study 8914876 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day + Enalapril 10 mg twice a day (group 1)
Number of subjects: 120
Study 8914876 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose Enalapril 10 mg twice a day (group 2)
Number of subjects: 120
Study 8914876 — intervention group
Group type: COMPARATOR
Intervention: High-dose Enalapril 20 mg twice a day (group 3)
Number of subjects: 120
Study 8914876 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan + Enalapril
Number of subjects: 120
Study 1802209 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict nutritional protocol covering needs and satisfying tastes and habits
Number of subjects: 93
Study 1802209 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum diet
Number of subjects: 93
Study 6407278 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride
Number of subjects: 28
Study 6407278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31744521 — intervention group
Group type: EXPERIMENTAL
Intervention: Bang® Pre-Workout Master Blaster® (BMB)
Number of subjects: 16
Study 31744521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 28479178 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG needle and syringe (BCG NS)
Number of subjects: 452
Study 28479178 — intervention group
Group type: EXPERIMENTAL
Intervention: Device A
Number of subjects: 452
Study 28479178 — intervention group
Group type: EXPERIMENTAL
Intervention: Device B
Number of subjects: 452
Study 26385034 — intervention group
Group type: EXPERIMENTAL
Intervention: Early beta-blocker therapy
Number of subjects: 14241
Study 26385034 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 14241
Study 23249415 — intervention group
Group type: EXPERIMENTAL
Intervention: Eminol® (grape extract) 700 mg
Number of subjects: 60
Study 23249415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21724659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol mesh-supported graft
Number of subjects: 25
Study 21724659 — intervention group
Group type: COMPARATOR
Intervention: Conventional vein grafts
Number of subjects: 25
Study 21724659 — intervention group
Group type: COMPARATOR
Intervention: Arterial grafts
Number of subjects: 25
Study 19502264 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg body weight at 0, 2, 6 weeks and then q 8 weeks for a total of 24 weeks, total of five doses)
Number of subjects: 27
Study 19502264 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment only)
Number of subjects: 27
Study 17052498 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 0
Study 17052498 — intervention group
Group type: COMPARATOR
Intervention: Vehicle preirradiation and postirradiation treatment
Number of subjects: 0
Study 17052498 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14519613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for depression and parenting skills enhancement
Number of subjects: 0
Study 14519613 — intervention group
Group type: COMPARATOR
Intervention: Mothers' support group
Number of subjects: 0
Study 14519613 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 11012497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 90
Study 11012497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% - Lidocaine 1%
Number of subjects: 90
Study 11012497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.375% - Lidocaine 1%
Number of subjects: 90
Study 11012497 — intervention group
Group type: COMPARATOR
Intervention: Control (Ropivacaine 0.5%)
Number of subjects: 90
Study 8774276 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy followed by IM injection of 5,000 IU hCG
Number of subjects: 64
Study 1727843 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light therapy
Number of subjects: 50
Study 1727843 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared light therapy
Number of subjects: 50
Study 1727843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6091474 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of ceftriaxone
Number of subjects: 81
Study 6091474 — intervention group
Group type: COMPARATOR
Intervention: Multidose cefazolin (one preoperative and three postoperative doses)
Number of subjects: 81
Study 6091474 — intervention group
Group type: COMPARATOR
Intervention: Multidose cefazolin
Number of subjects: 81
Study 31561727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-Bearing Total Ankle Replacement (MB-TAR)
Number of subjects: 100
Study 31561727 — intervention group
Group type: COMPARATOR
Intervention: Fixed-Bearing Total Ankle Replacement (FB-TAR)
Number of subjects: 100
Study 31561727 — intervention group
Group type: EXPERIMENTAL
Intervention: MB-TAR
Number of subjects: 100
Study 31561727 — intervention group
Group type: COMPARATOR
Intervention: FB-TAR
Number of subjects: 100
Study 29209814 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation (web-based care)
Number of subjects: 74
Study 29209814 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 74
Study 29209814 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine group
Number of subjects: 74
Study 29209814 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 74
Study 26479973 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose MenACWY-CRM vaccination series
Number of subjects: 751
Study 26479973 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose MenACWY-CRM vaccination series
Number of subjects: 751
Study 26479973 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose MenACWY-CRM with PCV13
Number of subjects: 751
Study 26479973 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose MenACWY-CRM with PCV13
Number of subjects: 751
Study 26479973 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccinations only
Number of subjects: 751
Study 25269467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants placed through skin flaps
Number of subjects: 75
Study 25269467 — intervention group
Group type: COMPARATOR
Intervention: Dental implants placed through oral mucosa
Number of subjects: 75
Study 23096987 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix‐assisted, tissue expander/implant reconstruction
Number of subjects: 70
Study 23096987 — intervention group
Group type: COMPARATOR
Intervention: Submuscular tissue expander/implant placement
Number of subjects: 70
Study 20594055 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration eucalyptus extract (0.6%)
Number of subjects: 97
Study 20594055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration eucalyptus extract (0.4%)
Number of subjects: 97
Study 20594055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 17331985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal lauric acid (C12) at different loads (0.2, 0.3, 0.4 kcal min(‐1) for 90 min)
Number of subjects: 24
Study 17331985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal lauric acid (C12) at different concentrations (40, 56, 72 mM at 0.4 kcal min(‐1) for 60 min)
Number of subjects: 24
Study 16260974 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSSsingle
Number of subjects: 8
Study 12243599 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/kg/d of amniotic fluid solution
Number of subjects: 30
Study 12243599 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg/d of amniotic fluid solution
Number of subjects: 30
Study 12243599 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL/kg/d of amniotic fluid solution
Number of subjects: 30
Study 10195535 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Hz
Number of subjects: 68
Study 10195535 — intervention group
Group type: EXPERIMENTAL
Intervention: 15/30 Hz
Number of subjects: 68
Study 10195535 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz
Number of subjects: 68
Study 10195535 — intervention group
Group type: COMPARATOR
Intervention: Sham-PENS (0 Hz)
Number of subjects: 68
Study 8562004 — intervention group
Group type: COMPARATOR
Intervention: AIDS prevention program led by teachers, developed with local AIDS experts, social scientists, and health educators; aimed to provide accurate information about AIDS, foster positive attitudes, and develop skills for assessing intended behavior.
Number of subjects: 804